Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 18/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | VHL | P40337 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359875 | 1.00 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL29383609 | 1.00 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL29802701 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL29378086 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL320637 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL23092274 | 0.97 | NR1H3 (0.95) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4951300 | 0.95 | NR1H3 (0.91) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL13764633 | 0.95 | NR1H3 (0.90) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL13764643 | 0.94 | NR1H3 (0.88) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL3979972 | 0.94 | NR1H3 (0.88) | NR1H3NR1H2RXRAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999055-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-05-25 | — | — | EP | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| CN-114126618-A | Method of treating meibomian gland dysfunction with liver X receptor agonists | 诺华股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-3236927-B1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2019-11-13 | — | — | EP | claimed |
| US-9399045-B2 | Inhibition of choroidal neovascularization | WASHINGTON UNIVERSITY (US) | 2016-07-26 | — | — | US | claimed |
| US-20160045549-A1 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | claimed |
| WO-2015187840-A2 | METHODS AND FORMULATIONS FOR TREATMENT OF OCULAR DISORDERS | DUKE UNIVERSITY (US) | 2015-12-10 | — | — | WO | claimed |
| US-9056091-B1 | Composition for regulation of liver X receptor | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-06-16 | — | — | US | claimed |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | SNU R&DB FOUNDATION (KR) | 2013-10-17 | — | — | US | claimed |
| EP-2615094-A2 | SESTERTERPENE COMPOUNDS AND USE THEREOF | SNU R & DB Foundation (KR) | 2013-07-17 | — | — | EP | claimed |
| WO-2006000577-A2 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | GALAPAGOS N.V. (BE) | 2006-01-05 | — | — | WO | claimed |
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | claimed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | claimed |
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | claimed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| JP-2004509161-A | — | — | 2004-03-25 | — | — | JP | claimed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 28/4885 |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | LIPC, LIPE, FABP4 | NR1H3 231/4885NR1H2 218/4885RXRA 1971/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | NR1H3 2/4885NR1H2 1/4885RXRA 12/4885 |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | NR1H2, NR1H3, NR1H4 | NR1H3 2/4885NR1H2 1/4885RXRA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.